Short-term, combined use of paracetamol and zidovudine does not alter the pharmacokinetics of either drug

Burger, D.M.; Pl, Meenhorst; Wj, Underberg; Jf, van der Heijde; Ch, Koks; Jh, Beijnen

doi:10.1016/0300-2977(95)90002-0

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent reports suggest that coadministration of zidovudine might potentiate APAP‐induced hepatotoxicity [ 17]. However, Burger et al [ 20] have shown neither drug to affect the pharmacokinetics of the other. The data from the cross sectional segment of this study is consistent with the latter finding as no significant difference was detected in either metabolic index between patients taking zidovudine and those not taking it.…”

Section: Discussionmentioning

confidence: 99%

“…A competition for glucuronic acid cofactor was suggested as a potential cause of reduced APAP clearance and, thereby, increased hepatotoxicity. However, it has been shown in vitro [ 18, 19] that different isoforms of UDP glucuronosyltransferase are responsible for the glucuronidation of AZT and APAP, and Burger et al [ 20] found no changes in the pharmacokinetics of either drug when coadministered. Metabolic drug interactions would therefore be unexpected.…”

Section: Introductionmentioning

confidence: 99%

“…Burger et al [20] have shown neither drug to affect the Protein-calorie malnutrition was identified as another…”

mentioning

confidence: 99%

“…However, it has been shown in vitro [18, The glucuronidation and sulphation capacities of the subjects were assessed using APAP as the probe. Spot 19] that different isoforms of UDP glucuronosyltransferase are responsible for the glucuronidation of AZT and urine samples were collected 4 h after ingestion of one 500 mg APAP tablet (Atasol ForteA, Frank W. Horner APAP, and Burger et al [20] found no changes in the pharmacokinetics of either drug when coadministered.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Glucuronidation and sulphation of paracetamol in HIV‐positive patients and patients with AIDS

O’Neil

Pezzullo

Girolamo

et al. 1999

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aims To gauge the effect of disease state and disease progression on the glucuronidation and sulphation of paracetamol (APAP) among HIV-positive patients and patients with AIDS. Methods The extent of APAP glucuronidation and APAP sulphation was assessed using a spot urine sample collected 4 h after the oral administration of 500 mg of APAP to 108 patients with AIDS or HIV infection. The molar concentrations of APAP and its glucuronide and sulphate metabolites were determined using a validated h.p.l.c. method and glucuronidation and sulphation indices were constructed using APAP metabolite/APAP molar concentration ratios. Results No effect of disease state, AIDS vs asymptomatic HIV positive vs control, on APAP glucuronidation or sulphation was observed. The patient population was studied over time and disease progression also did not significantly alter the calculated glucuronidation and sulphation indices. The effect of the concomitant administration of other therapeutic agents was assessed and in the cross sectional portion of the study dapsone appeared to significantly decrease APAP sulphation as did lamivudine. In the longitudinal portion of the study the latter effect was not observed but zidovudine was seen to increase APAP glucuronidation. The data also indicates that APAP glucuronidation may be reduced in patients who are >10% below their ideal body weight.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Burger et al [20] have shown neither drug to affect the Protein-calorie malnutrition was identified as another…”

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Glucuronidation and sulphation of paracetamol in HIV‐positive patients and patients with AIDS

O’Neil

Pezzullo

Girolamo

et al. 1999

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

Hepatotoxicity of Antiviral Agents

Styrt

Freiman²

1995

Gastroenterology Clinics of North America

View full text Add to dashboard Cite

Drug Interactions with Paracetamol

Toes

Jones²,

Prescott

2005

American Journal of Therapeutics

View full text Add to dashboard Cite

Paracetamol (acetaminophen) is one of the most commonly used analgesic antipyretic drugs worldwide, and it is widely available by prescription and over the counter (OTC). Fortunately, few clinically significant drug interactions have been documented. There is probable potentiation of hepatotoxicity following an overdose from the paracetamol metabolite NAPQI by enzyme-inducing drugs. There is considerable controversy regarding the possible interaction with warfarin in its potential to increase its anticoagulant effects because of discrepancies between observational studies and those in healthy volunteers. Otherwise, no serious adverse drug interactions with therapeutic doses of paracetamol have been confirmed in humans. Because the absorption of paracetamol is so dependent on gastric emptying, other drugs that alter gastric emptying can change its pharmacokinetics; but this would not cause serious adverse effects. Although animal experiments have demonstrated that many compounds can modify paracetamol hepatotoxicity, these are unlikely to be important at therapeutic doses.

show abstract

Short-term, combined use of paracetamol and zidovudine does not alter the pharmacokinetics of either drug

Cited by 4 publications

References 0 publications

Glucuronidation and sulphation of paracetamol in HIV‐positive patients and patients with AIDS

Glucuronidation and sulphation of paracetamol in HIV‐positive patients and patients with AIDS

Hepatotoxicity of Antiviral Agents

Drug Interactions with Paracetamol

Contact Info

Product

Resources

About